Foreign or Domestic CARs: Receptor Ligands as Antigen-Binding Domains

Medical Sciences

Donald R. Shaffer¹  Penghui Zhou¹ 

[1] Cancer Immunology & AIDS Department, Dana-Farber Cancer Institute, Boston, MA 02215, USA; E-Mail:

关键词: chimeric antigen receptor;    adoptive immunotherapy;    immunology;    cancer;   

DOI  :  10.3390/medsci2010023

来源: mdpi

【 摘 要 】

Chimeric antigen receptors (CARs) are increasingly being used in clinical trials to treat a variety of malignant conditions and recent results with CD19-specific CARs showing complete tumor regressions has sparked the interest of researchers and the public alike. Traditional CARs have been generated using single-chain variable fragments (scFv), often derived from murine monoclonal antibodies, for antigen specificity. As the clinical experience with CAR T cells grows, so does the potential for unwanted immune responses against the foreign transgene. Strategies that may reduce the immunogenicity of CAR T cells are humanization of the scFv and the use of naturally occurring receptor ligands as antigen-binding domains. Herein, we review the experience with alternatively designed CARs that contain receptor ligands rather than scFv. While most of the experiences have been in the pre-clinical setting, clinical data is also emerging.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.